Functional characterization of the matrix metalloproteinase-1 cigarette smoke-responsive region and association with the lung health study by Alison M Wallace et al.
Wallace et al. Respiratory Research 2012, 13:79
http://respiratory-research.com/content/13/1/79RESEARCH Open AccessFunctional characterization of the matrix
metalloproteinase-1 cigarette smoke-responsive
region and association with the lung health study
Alison M Wallace1,2, Becky A Mercer2, Jianqing He1, Robert F Foronjy3, Domenico Accili4, Andrew J Sandford1,5,
Peter D Paré1,5 and Jeanine M D’Armiento2*Abstract
Background: Prior studies have demonstrated that the distal 1.5 kb of the MMP-1 promoter is fundamental in
directing the induction of the MMP-1 gene by cigarette smoke.
Methods: To characterize the genetic variants in the MMP-1 cigarette smoke-responsive element, deep
re-sequencing of this element was performed on DNA samples from participants in the Lung Health Study.
Furthermore, evidence of Sp1 binding to the MMP-1 promoter was assessed using chromatin immunoprecipitation
assays and the influence of cigarette smoke exposure on this interaction was evaluated in cultured human small
airway epithelial cells.
Results: Ten polymorphisms (four novel) were detected in the cigarette smoke-responsive element. Chromatin
immunoprecipitation assays to assess the protein-DNA interactions at Sp1 sites in the MMP-1 promoter showed
increased binding to the Sp1 sites in the cigarette smoke-responsive element in small airway epithelial cells treated
with cigarette smoke extract. In contrast, a Sp1 site outside of the element exhibited the opposite effect. None of
the polymorphisms were more prevalent in the fast decliners versus the slow decliners (fast decliners = mean
−4.14% decline in FEV1% predicted per year vs. decline in FEV1% predicted per year).
Conclusions: Sequencing analyses identified four novel polymorphisms within the cigarette smoke-responsive
element of the MMP-1 promoter. This study identifies functional activity within the cigarette smoke-responsive
element that is influenced by cigarette smoke and examines this region of the promoter within a small patient
population.
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Chronic obstructive pulmonary disease (COPD), which
is characterized by both emphysema and inflammatory
scarring and narrowing of small airways, is a major cause
of morbidity and mortality worldwide [1]. Cigarette
smoke is the single most important factor in the devel-
opment of COPD. Not all smokers develop COPD, how-
ever, smoking is responsible for up to 90% of cases in
the developed world [2]. Current diagnostic and thera-
peutic options for this disease are limited.* Correspondence: jmd12@columbia.edu
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reproduction in any medium, provided the orMuch attention has been given to the role of matrix
metalloproteinases (MMPs), a family of zinc-dependent
proteinases with the capacity to degrade both elastin and
collagen, in the pathogenesis of COPD. Although the ori-
ginal protease-antiprotease imbalance theory of COPD fo-
cused on destruction of elastin in the lung, there is
evidence that collagen degradation is important as well. In
1992 D’Armiento and coworkers [3] found that over-
expression of human MMP-1 (interstitial collagenase) in
transgenic mice led to the development of emphysema.
Subsequent studies demonstrated that the important tar-
get for MMP-1 was type III collagen and that adult-onset
emphysema developed in strains of mice expressing
MMP-1 in the lung [3,4]. In humans, increased levels ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells, have been reported in the lungs of patients with em-
physema but not in normal controls [5,6]. In addition,
Type II pneumocytes are also known to express MMP-1
[5]. In vitro, direct exposure of human small airway epi-
thelial cells to cigarette smoke induced MMP-1 mRNA
and protein expression via the extracellular-signal-
regulated kinases (ERK)/mitogen activated protein kinase
(MAPK) pathway and human emphysematous lung tissue
showed significantly increased ERK activity compared to
control lung [7]. Through deletion studies our laboratory
identified that the distal 1.5 kb of the MMP-1 promoter
was fundamental to the direct induction of the MMP-1
gene by cigarette smoke and that Sp1 is activated by
cigarette smoke [8].
Only a small subset of smokers develop COPD and
once established, the disease process varies greatly from
person to person. There is an underlying genetic suscep-
tibility determining both the onset and the course of the
disease.The heterogeneity of this disease suggests that
there may be some genes and/or gene variants that con-
tribute to COPD in general, while other genes and/or
gene variants may be relevant only for a particular
phenotype. It is unknown whether DNA sequence vari-
ation in the MMP-1 gene contributes to the individual
susceptibility and/or phenotypic variation. We hypothe-
sized that DNA sequence variation in this responsive
element could be associated with a COPD phenotype,
accelerated lung function decline, and if an association
was found may suggest a functional role of these poly-
morphisms. Furthermore, based on our previous work,
we speculated that gene variants could modulate Sp1
binding and therefore influence smokers’ susceptibility
to COPD through variations in MMP-1 expression.
In the present study the genetic variants in the cigarette
smoke-responsive region were characterized, with particu-
lar interest in identifying single nucleotide polymorphisms
(SNPs) altering Sp1 binding sequences. Chromatin immu-
noprecipitation (ChIP) assays were performed to assess
the protein-DNA interactions at Sp1 sites in the MMP-1
promoter to define the functional binding sites and deter-
mine whether or not these sites were influenced by
cigarette smoke exposure in cultured human small airway
epithelial cells. An association study was also performed
to test whether SNPs within this region were associated
with an accelerated rate of decline in lung function in the
Lung Health Study (LHS) participants.
Methods
Study population
DNA for re-sequencing and genetic association studies
was obtained from subjects selected from participants in
Phase I of the National Heart, Lung, and Blood Institute
LHS. Details of the study have been previously published[9]. Briefly, study participants were current smokers,
35–60 years of age, who had mild to moderate airflow
obstruction (FEV1 55–90% predicted and FEV1/FVC
≤ 0.70). The primary outcome variable was rate of de-
cline in post-bronchodilator FEV1 over a follow-up
period of five-years. A subset of 582 individuals were
selected from the 5,887 subjects in the LHS because they
represent phenotypic extremes. They include the 277
subjects (fast decliners) who continued to smoke during
the first five-years of follow-up, had yearly measure-
ments of FEV1, and showed the fastest decline in lung
function over that time (FEV1% predicted change =
−4.14%/year), and the 305 subjects (slow decliners) who
continued to smoke and exhibited the slowest decline
over the same period of time (FEV1% predicted change
= +1.07%/year). Of the subset, 551 non-Hispanic white
participants (261 fast decliners and 290 slow decliners)
were selected for the association study. This study was
approved by the University of British Columbia/Provi-
dence Health Care Research Ethics Board.Identification of DNA sequence variants
High-throughput sequencing of the MMP-1 cigarette
smoke-responsive element (~1.5 kb) was performed at
the Genome Sciences Centre at the British Columbia
Cancer Agency using Applied Biosystems chemistries
(ABI BigDye™ v3.1 Terminator Chemistry) and equip-
ment (ABI 3730xl). Sequencing PCR primers were
designed using Overlapping Primersets (http://www2.
eur.nl/fgg/kgen/primer/Overlapping_Primers.html). The
primer sequences were: Region 1 (−3660 to −4343) sense
5’-CTAAAAGCTCTGCAGGCCAC-3’ and antisense 5’-C
GCTTAGGCTGGAGTGTAGG-3’ region 2 (−3510 to
−4147) sense 5’-GGCATGCAAATCACCAAAA-3’ and
antisense 5’-AATCCTCCCCTTCAAGCTGT-3’ region 3
(−2890 to −3748) sense 5’-TCTTAGGAGAGTAAAAGT
CATGGACA-3’ and antisense 5’-TTCTTGGTTGCTTCA
TGCTG-3’. For the purpose of sequencing, a M13 forward
linker was added to the 5’ end of the forward primers
(TGTAAAACGACGGCCAGT) and a M13 reverse linker
was added to the 5’ end of the reverse primers
(CAGGAAACAGCTATGAC). Sequencing was performed
using M13 universal sequencing primers. PCR conditions
were as follows: initial denaturation at 95°C for 15 minutes;
35 cycles at 94°C for 30 seconds, 58°C for 30 seconds, and
72°C for 50 seconds; and final extension at 72°C for
10 minutes. Discovery of sequence variation was per-
formed using novoSNP [10], which has higher sensitivity
and specificity than PolyPhred [11]. Each SNP had a com-
pletion rate of greater than 90% in all subjects and a
Hardy-Weinberg equilibrium P value of greater than 0.01
in non-Hispanic whites.
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ChIP was performed using the Upstate (Millipore) ChIP
Kit (Billerica, MA, USA) according to the manufacturer’s
instructions. Chromatin was harvested from human
small airway epithelial cells (Lonza, Walkersville, MD)
that were seeded at 7.5×105 cells per T75 flask (BD
Falcon, San Jose, CA) and treated with control media or
5% cigarette smoke extract at 80% confluence for
24 hours, prior to crosslinking, as previously described
[7]. Cells between passages two and six were used in all
in vitro experiments. Conditions were established to ob-
tain chromatin fragments 200–600 bp in length using
the Fisher Scientific F 550 Sonic Dismembrator. Immu-
noselection of chromatin fragments was performed
using 2 ug of rabbit polyclonal Sp1 antibody (sc-59 X;
Santa Cruz Biotechnology, Santa Cruz, CA). An aliquot
that was immunoprecipitated without antibody was used
as a negative control. Detection of specific DNA
sequences was performed using real-time quantitative
PCR with the use of an ABI Prism 7900HT Sequence
Detection System (Applera Corporation, Norwalk, CT,
USA) using the following primers: -3987 site (83 bp
amplicon) sense 5’-TCTCCAGTAAGGCTGGGTGT-3’
and antisense 5’-CTGGCCTCAAGCAGTTCTCT-3’;-
3455 site (117 bp amplicon) sense 5’-TGCAGACACC-
TACTATGTTGAG-3’ and antisense 5’-ATAATGTCAC-
CATGCCACCAC-3’; and-2209 site (68 bp amplicon)
sense 5’-TAGAGAAGG GAGGAAAAAGCAG-3’ and
antisense 5’-GTTGGAAA TAGAGCCTTGGAGT-3’.Statistical analysis
The associations were analyzed by binary logistic regres-
sion to adjust for potential confounding factors. The
outcome was a dichotomous variable, that is, fast decline
or slow decline. Potential confounding factors included
in the analysis were age, sex, smoking history (expressed
as pack-years), initial level of lung function (pre-
bronchodilator FEV1 percent predicted), and methacho-
line responsiveness. The latter variable was expressed as
a two-point dose–response slope as previously described
[12]. Hardy–Weinberg equilibrium was calculated usingTable 1 Characteristics of study subjects
Slow decliners (n = 290)
Age 47.4 ± 0.4
Male (%) 193 (66.6)
Pack-years 38.3 ± 1.1
Baseline FEV1, % predicted* 79.8 ± 0.5
Methacholine response† −8.0 ± 0.9
Data are presented as percent or mean (SE).
*Lung function at the start of the study as measured percent predicted FEV1 (postb
†Measurement of the responsiveness of the airways to methacholine expressed as
administered (O'Connor et al. 1995).an online calculator (http://www.oege.org/software/hwe-
mr-calc.shtml) [13]. Minimal detectable odds ratio at
P = 0.05 and 0.80 power for different minor allele fre-
quency (MAF) in the case–control association study was
performed using PGA Power Calculator software [14].
All other tests were performed using the JMP Statistics
software package (SAS Institute Inc., Cary, NC). Statis-
tical significance was defined at the 5% level.
Results
Descriptive statistics and univariate comparisons between
fast decliners and slow decliners are summarized in Table 1.
Age, sex, smoking history (pack-years), baseline FEV1%
predicted postbronchodilator, and methacholine response
were borderline or significantly different between the two
groups. Therefore, the association of genotypes with decline
of lung function was analyzed by logistic regression to ad-
just for these factors.
Re-sequencing of the MMP-1 cigarette smoke-responsive
region revealed a total of ten polymorphisms (Table 2).
Four of these genetic variants have not been previously
reported in the National Center for Biotechnology Informa-
tion SNP database (dbSNP). The presence and frequency of
six dbSNPs were confirmed; three previously reported
dbSNPs were not identified.
Several transcription factors are induced by cigarette
smoke and have been shown to be important for regulat-
ing MMP-1 expression [8]. Since not all smokers de-
velop COPD, despite smoking being the most important
risk factor for the development of this disease, gene var-
iants in the cigarette smoke-responsive element could
provide a susceptibility locus for smoke-induced lung
disease. None of the polymorphisms in this region cor-
respond specifically to the Sp1 sites at positions −3987
and −3455 that through site-directed mutagenesis we
know are important for regulating MMP-1 expression
(data not shown). Furthermore, other transcription fac-
tor binding sites of interest, such as AP-1 sites at posi-
tions −4293 and −4210 and c-Ets-1 sites at positions
−3838 and −3344, did not overlap specifically with any
polymorphisms identified in this cohort of smokers, pos-
sibly suggesting that the transcription factor bindingFast decliners (n = 261) P value
49.6 ± 0.4 0.0007
155 (59.4) 0.082
43.2 ± 1.2 0.002
74.6 ± 0.6 <0.0001
−24.2 ± 2.1 <0.0001
ronchodilator).
percent decline in FEV1 per final cumulative dose of methacholine
Table 2 Identification of polymorphisms in MMP-1 cigarette smoke-responsive element
SNP* SNP ID WW† WM† MM† NC{ Not amplified for this SNP Total N Failed % W% M%
17 T/A rs484915 167 265 126 4 20 582 4.1 53.7 46.3
352 G/A rs470307 554 9 0 0 19 582 3.3 99.2 0.8
412 T/A NA 571 5 0 0 6 582 1.0 99.6 0.4
712 G/A rs2408490} 368 149 16 4 45 582 8.4 83.0 17.0
724 T/A rs12279710 534 3 0 1 44 582 7.7 99.7 0.3
759 T/G rs7107224 391 162 19 5 5 582 1.7 82.5 17.5
816A/C rs1155764} 383 157 21 19 2 582 3.6 82.3 17.7
1164C/T rs34695796 537 19 1 9 16 582 4.3 98.1 1.9
1227 G/A NA 558 6 0 2 16 582 3.1 99.5 0.5
1283 G/A NA 554 5 0 7 16 582 4.0 99.6 0.4
1284 G/A NA 499 49 3 15 16 582 5.3 95.0 5.0
* Position in AF023338.
† “W” denotes wild-type allele; “M” denotes mutant allele.
{Results are not consistent between forward primer sequencing and reverse primer sequencing.
}Rs2408490 and rs1155764 are in complete LD with r2 = 1 in Hapmap database.
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the above mentioned binding sites, these polymorphisms
could affect the binding of other regulatory proteins that
control the activity of the promoter and influence
mRNA and protein levels.
Our previous studies have shown that in lung epithe-
lial cells Sp1 modifies the expression of MMP-1 during
smoke exposure [8]. Therefore, we next investigated the
mechanism by which Sp1 regulates MMP-1 expression.
To test the hypothesis that Sp1 is a key regulator of
MMP-1 expression in intact cells, we performed ChIP
assays on human small airway epithelial cells, in vitro.
The DNA corresponding to the Sp1 sites in the cigarette
smoke-responsive element was amplified and chromatin
immunoprecipitated with an antibody to Sp1. The data
demonstrated that Sp1 is recruited onto the MMP-1
promoter in vitro. The results show an interaction
between Sp1 and the MMP-1 promoter at baseline
and that there is a significant increase in binding in cul-
tured human small airway epithelial cells treated with
cigarette smoke extract (Figure 1a-b). In contrast, the
Sp1 site at position −2209, which is outside of the
cigarette smoke-responsive element, exhibited the op-
posite effect (Figure 1c).
Association analyses of the individual SNPs with rate
of decline in lung function in the fast decliners and slow
decliners showed no significant associations between
genetic variants in the MMP-1 cigarette smoke-
responsive element and this COPD phenotype in non-
Hispanic whites (Table 3). Minimal detectable odds
ratios for different MAFs and different genetic models
are shown in Figure 2. The study design has 80% power
to detect associations with odds ratios of 2.0 for the five
SNPs with a MAF ≥ 0.05 in co-dominant and dominant
genetic models.Discussion
MMP-1 is important in the pathogenesis of COPD with
increased expression being a common finding in patients
with this disease [5,6,15]. Animal studies have shown
that MMP-1 plays a key role in the initiation of the dis-
ease process [3]. Previous studies from our laboratory
have identified the distal MMP-1 promoter to be funda-
mental for the direct activation of the MMP-1 promoter
by cigarette smoke [8]. Studies of genetic variants in the
MMP-1 promoter are important because identification
of functional polymorphisms will lead to a greater
understanding of the regulatory mechanisms involved in
both health and disease, and may provide useful know-
ledge for identifying at-risk individuals to allow for early
interventions.
This present study generated the following three
important findings. First, the genetic variants in the
MMP-1 cigarette smoke-responsive element were fur-
ther characterized and four novel polymorphisms identi-
fied, as well as the confirmation of six previously
reported genetic variants. Second, an important inter-
action between Sp1 binding and the MMP-1 cigarette
smoke-responsive element in human small airway epi-
thelial cells exposed to cigarette smoke extract was
documented. Sp1 protein binding was influenced by
cigarette smoke and this DNA-protein interaction oc-
curred specifically in the cigarette-smoke responsive
element and did not appear to occur outside of the core
regulatory region. Third, polymorphisms in the cigarette
smoke-responsive element were not more prevalent in
subjects who had an accelerated decline in lung function
over five-years of the Lung Health Study.
MMP-1 is tightly regulated at the level of transcrip-
tion, post-transcription, and post-translation; it is also
known that MMP-1 expression is influenced by genetic
Figure 1 Sp1 action on the MMP-1 promoter is shown by the fold change in specific DNA sequences detected by qPCR. MMP-1 ChIP assays
were done in cell cultures from human small airway epithelial cells with and without cigarette smoke extract (CSE) treatment using an antibody
to Sp1 or nonimmune serum. We amplified DNA using primers spanning two Sp1 binding sites within the cigarette smoke-responsive element
(a,b) and one sequence outside of this element (c). Samples from each experiment were run in triplicate. Data are mean ± SEM. *P < 0.05.
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responsive element spanning approximately 1.5 kb, a
total of ten polymorphisms were identified via re-se-
quencing. Four novel polymorphisms were revealed.
These data are important because they allow researchers
to further analyze the contribution of genetic poly-
morphisms to the development and progression of mul-
tiple diseases associated with MMP-1 expression. In
addition to the established role of MMP-1 in COPD, ele-
vated expression of MMP-1 has been associated with a
variety of pathological conditions such as rheumatoid
and osteoarthritis, atherosclerosis, Alzheimer disease,
and cancer [17]. There is a functional polymorphism in
the MMP-1 promoter (rs1799750) described by Rutter
et al. that has been associated with numerous malignant
processes [18]. Further understanding of the genetic var-
iants in the MMP-1 promoter, and more specifically the
cigarette smoke-responsive element, may provide add-











17 T/A rs484915 102178458 73 (26%) 136 (49%
352 G/A rs470307 102178123 274 (98%) 7 (2%
412 T/A NA 102178063 283 (99%) 3 (1%
712 G/A rs2408490 102177763 191 (72%) 64 (24%
759 T/G rs7107224 102177716 200 (71%) 72 (25%
816 A/C rs1155764 102177659 196 (71%) 69 (25%
1164 C/T rs34695796 102177311 263 (96%) 12 (4%
1227 G/A NA 102177248 277 (99%) 3 (1%
1283 G/A NA 102177192 274 (99%) 3 (1%
1284 G/A NA 102177191 247 (91%) 23 (8%diseases and help define the role of smoking as a risk
factor.
Understanding the molecular mechanisms controlling
MMP-1 expression may identify potential targets for the
prevention of diseases and degenerative conditions asso-
ciated with dysregulation of MMP-1. The first cis-
promoter element found to be responsible for regulating
MMP-1 gene expression was AP-1 [19]. Previous studies
by our laboratory have identified a number of transcrip-
tion factors, including AP-1, that are important for regu-
lating MMP-1 promoter activity [8]. Further analysis in
the present study revealed two Sp1 sites (−3987 and
−3455) in the cigarette smoke-responsive element that
have now been analyzed using a ChIP assay to assess the
functional importance of these sites in vitro. Our data
demonstrates that these are functional binding sites and
that binding of Sp1 to the MMP-1 promoter is influ-
enced by cigarette smoke. This is in contrast to the
decreased binding of Sp1 to the MMP-1 promoter-Hispanic whites
ers Fast decliners P value
MM WW WM MM
) 70 (25%) 78 (31%) 117 (47%) 53 (21%) 0.35
) 0 249 (99%) 2 (1%) 0 0.18
) 0 257 (99%) 2 (1%) 0 1.00
) 9 (3%) 162 (67%) 73 (30%) 6 (2%) 0.28
) 11 (4%) 175 (68%) 77 (30%) 7 (3%) 0.44
) 11 (4%) 171 (67%) 76 (30%) 9 (3%) 0.47
) 0 244 (97%) 7 (3%) 1 (0%) 0.36
) 0 251 (99%) 3 (1%) 0 1.00
) 0 251 (99%) 2 (1%) 0 1.00
) 2 (1%) 225 (90%) 25 (10%) 1 (0%) 0.74
Figure 2 The detectable relative risk given the number of
subjects is shown for a variety of marker allele frequencies
using different genetic models.
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sponse to cigarette smoke exposure. Not only are these
sites functional, they also occur in a region harbouring a
number of common SNPs. Although the genetic variants
identified did not directly alter the primary transcription
factor binding sites we assessed, they may influence the
binding of chromatin modifying proteins resulting in a
measurable functional effect on promoter activity. Un-
fortunately, this study is limited by the fact that suscepti-
bility to COPD (i.e. accelerated decline in lung function
with smoking) and Sp1 binding to the MMP-1 gene
were not measured in the same individuals since the ap-
propriate cells were not available from the LHS partici-
pants. However, the findings that the SNPs identified do
not directly alter the Sp1 bindings sites at the DNA level
and are not associated with rapid decline in lung func-
tion are interesting and potentially important. It may be
that since Sp1 plays a significant role regulating MMP-1
expression these sites are conserved. These negative
results do suggest that the SNPs are not a risk for rapid
decline in lung function among smokers.
COPD is a chronic disease of complex phenotype
[20,21]. There is even speculation that COPD represents
a syndrome comprised of many rare diseases [22]. In the
present association study the relationship between poly-
morphisms in the cigarette smoke-responsive element
and one COPD phenotype, rate of decline in lung func-
tion, was tested. No significant associations were found
despite the sufficient power of the study. Such a finding
however is not surprising since the results of the basic
studies suggest that MMP-1 expression is critical in the
pathogenesis of lung destruction and generation of theemphysema phenotype [3]. It will be necessary in future
detailed human studies to test for an association of the
cigarette smoke-responsive element polymorphisms with
CT evidence of lung destruction. Unfortunately, CT data
was not available on the LHS participants and therefore
we were unable to investigate this further in our popula-
tion. Additionally, our lab has demonstrated that
cigarette smoke directly induces the expression of
MMP-1 highlighting the importance of MMP-1 in the
susceptibility to lung destruction in smokers [3]. All
LHS participants exhibit some degree of airflow limita-
tion, indicating that they are already responsive to the
damaging effects of cigarette smoke. Therefore, to test
the importance of this element in disease susceptibility it
will be necessary to assess these genetic variants in alter-
native well-characterized cohorts of smokers with and
without COPD, as well as normal non-smokers.
We acknowledge several limitations to the present study
in addition to the issues outlined above. Although an asso-
ciation between the MMP-1 polymorphisms and rate of
decline in lung function was not identified, these poly-
morphisms may influence other COPD-related pheno-
types. We know that lung function normally declines as
part of the aging process, while accelerated lung function
decline is a hallmark of COPD [23,24], therefore, the use
of this phenotype seems reasonable for genetic association
studies and decline in lung function over time has been a
common end point in clinical trials of COPD therapies
[25,26]. However despite the rigor of the lung function
phenotyping in the LHS, the five-year period of follow-up
may not be sufficient to clearly separate groups whose de-
cline in lung function varied significantly over time. In-
deed, the use of this single COPD phenotype and a short
follow-up period are limitations of this study. On the other
hand our group has previously identified susceptibility var-
iants in candidate genes using this approach [27,28]. The
association study was limited to non-Hispanic white sub-
jects but the genetic basis of COPD may differ between ra-
cial/ethnic groups as several COPD association studies
have shown distinct results within different races. Indeed,
it is known that MMP-1 polymorphisms are associated
with diseases such as cancer in other ethnic groups
[29,30]. Therefore, it will be of interest to further investi-
gate the role of these polymorphisms in alternative racial/
ethnic populations. Future studies may also include haplo-
type analysis to fully characterize the genetic architecture
of this region.
Conclusions
In conclusion, the genetic variants in the MMP-1
cigarette smoke-responsive element have been further
characterized revealing four novel polymorphisms. Evi-
dence has been generated providing insight into the
transcriptional regulation of the MMP-1 promoter in
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have a significant impact on the understanding of
many age-associated degenerative disease processes.
COPD association studies are challenging since COPD
is a heterogeneous condition and many phenotypes
exist. Although a significant association between these
MMP-1 polymorphisms and an accelerated rate of de-
cline in lung function in subjects with some degree of
airflow limitation was not identified, future studies
performed on a cohort of smokers with and without
disease needs to be carried out to determine if the
SNPs in the MMP-1 promoter associate with disease
susceptibility as would be predicted from the basic
bench research. Furthermore, future studies are
planned to further elucidate the mechanisms regulat-
ing MMP-1 expression and the functional conse-
quences of this altered expression, which includes
mapping out which transcription factor binding sites,
if any, are altered by SNPs in this region and determin-
ing the functionality. As we found with Sp1, AP-1, and
c-Ets-1 binding sites, we speculate that other tran-
scription factor binding sites in this region may be
highly conserved and therefore unaltered. Despite this,
although not directly altering the binding of transcrip-
tion factors, gene variants in this region could influ-
ence the multi-protein complexes that are formed
during transcription and modulate MMP-1 expression.Competing interests
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